M. A. Amani¹ , S. Miraoui¹ , M. J. Yousfi²

1 Department of Endocrinology, 1st November 1954 University Hospital of Oran, Algeria
2 Department of Urology, 1st November 1954 University Hospital of Oran, Algeria
Author    Correspondence author
International Journal of Clinical Case Reports, 2016, Vol. 6, No. 31   doi: 10.5376/ijccr.2016.06.0031
Received: 06 Nov., 2016    Accepted: 12 Dec., 2016    Published: 13 Dec., 2016

This is an open access article published under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Amani M.A., Miraoui S. and Yousfi M.J., 2016, A Hidden Secondary Hyperparathyroidism: A Case Report, International Journal of Clinical Case Reports, 6(31): 1-2 (doi: 10.5376/ijccr.2016.06.0031)

The secondary hyperparathyroidism is defined by an elevated parathyroid hormone (PTH) secondary to a decrease in calcemia. We report the case of a 15-year old female, followed for 3 years at the nephrology department for a nephrocalcinosis and which was addressed to us for the suspicion of a primary hyperparathyroidism. We noted in her personal history renal lithiasis.

 

The physical examination found a tooth dystrophy with decalcified teeth and diffuse bone pain. First blood tests: calcemia: 85mg/L (80-105), phosphoremia: 55mg/L (40-70) and PTH: 147.6pg/ml high (15-65). Second blood tests: calcemia: 90.85mg/L (81-104), phosphoremia: 40.14mg/L (25-46) and PTH: 169.4pg/ml high (15-65). The blood tests were completed with a dosage of 25-hydroxy-vitamin D: 11ng/ml (deficiency), 24 hours calciuria: 198mg/24h (4.4mg/Kg/24h), high. The renal ultrasound showed a nephrocalcinosis. The patient received a vitamin D treatment than the normalizing of the vitamin D was obtained (30.53ng/ml) and PTH too (56pg/ml, standards: 15-80). The diagnosis of a primary hyperparathyroidism will be retained after eliminating a secondary hyperparathyroidism.

Secondary hyperparathyroidism; Hypercalcemia; Vitamin D; Nephrocalcinosis